PlainRecalls
FDA Drug Moderate Class II Terminated

MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL), 10 mL Multiple-Dose Vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0703-0045-01.

Reported: March 3, 2021 Initiated: February 10, 2021 #D-0282-2021

Product Description

MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL), 10 mL Multiple-Dose Vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0703-0045-01.

Reason for Recall

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
N/A
Distribution
Product was distributed nationwide in the USA and Puerto Rico.
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL), 10 mL Multiple-Dose Vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0703-0045-01.. Recalled by Teva Pharmaceuticals USA. Units affected: N/A.
Why was this product recalled?
Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 3, 2021. Severity: Moderate. Recall number: D-0282-2021.